Effect of Background Diuretic Therapy on the Clinical Efficacy of SGLT2 Inhibitors in Patients of Heart Failure with Reduced Ejection Fraction: Current Evidence
Keywords:
SGLT2 inhibitors, heart failure,, DELIVER,, EMPEROR-ReducedAbstract
Sodium-glucose cotransporter-2 (SGLT2) inhibitors are a fundamental therapy for heart failure with reduced ejection fraction
(HFrEF). The clinical efficacy of SGLT2 inhibitors in the presence of background diuretic therapy has been questioned, mainly
because of the overlapping diuretic mechanism of action. However, recently, data analysis from two landmark trials, DELIVER
and EMPEROR-Reduced, has attempted to settle this question. Both analyses demonstrate a consistent benefit of SGLT2
inhibitors across a wide range of background diuretic therapy. This brief communication sheds light on the key findings from
these scientific studies
Downloads
Published
Issue
Section
License
All open access articles published in IJCP are distributed under the terms of the CC BY-NC 4.0 license (Creative Commons Attribution-Non-Commercial 4.0 International Public License). This license permits unrestricted use, distribution, and reproduction of the articles in any medium for non-commercial purposes, provided that: The original authorship is properly and fully attributed. The IJCP is cited as the original place of publication with correct citation details. If an original work is reproduced or disseminated in part or as a derivative work, this must be clearly indicated. No articles are reproduced for commercial use without prior consent from the IJCP. All licensing requests and permissions for commercial use will be managed by the Publisher.
